Key Prognostic Value of Lysosomal Protein Transmembrane 5 in Kidney Renal Clear Cell Carcinoma

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi:10.3322/caac.21551
   PubMed Web of Science ®Google Scholar
• Joosten SC, Smits KM, Aarts MJ, et al. Epigenetics in renal cell cancer: mechanisms and clinical applications. Nat Rev Urol. 2018;15(7):430–451. doi:10.1038/s41585-018-0023-z
   PubMed Web of Science ®Google Scholar
• Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:17009. doi:10.1038/nrdp.2017.9
   PubMed Web of Science ®Google Scholar
• Lai Y, Zeng T, Liang X, et al. Cell death-related molecules and biomarkers for renal cell carcinoma targeted therapy. Cancer Cell Int. 2019;19:221. doi:10.1186/s12935-019-0939-2
   PubMed Web of Science ®Google Scholar
• Iacovelli R, Verzoni E, Braud F, et al. First line treatment of metastatic renal cell carcinoma: two standards with different toxicity profile. Cancer Biol Ther. 2014;15(1):19–21. doi:10.4161/cbt.27150
   PubMed Web of Science ®Google Scholar
• Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15(2):81–94. doi:10.1038/nrclinonc.2017.166
   PubMed Web of Science ®Google Scholar
• Santoni M, Pantano F, Amantini C, et al. Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma. Biochim Biophys Acta. 2014;1845(2):221–231. doi:10.1016/j.bbcan.2014.01.007
   PubMed Web of Science ®Google Scholar
• Pak Y, Glowacka WK, Bruce MC, et al. Transport of LAPTM5 to lysosomes requires association with the ubiquitin ligase Nedd4, but not LAPTM5 ubiquitination. J Cell Biol. 2006;175(4):631–645. doi:10.1083/jcb.200603001
   PubMed Web of Science ®Google Scholar
• Li X, Su Y, Zhang J, et al. LAPTM5 plays a key role in the diagnosis and prognosis of testicular germ cell tumors. Int J Genomics. 2021;2021:8816456. doi:10.1155/2021/8816456
   PubMed Web of Science ®Google Scholar
• Glowacka WK, Alberts P, Ouchida R, et al. LAPTM5 protein is a positive regulator of proinflammatory signaling pathways in macrophages. J Biol Chem. 2012;287(33):27691–27702. doi:10.1074/jbc.M112.355917
   PubMed Web of Science ®Google Scholar
• Adra CN, Zhu S, Ko J-L, et al. LAPTM5: a novel lysosomal-associated multispanning membrane protein preferentially expressed in hematopoietic cells. Genomics. 1996;35(2):328–337. doi:10.1006/geno.1996.0364
   PubMed Web of Science ®Google Scholar
• Wang X, Trotman LC, Koppie T, et al. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell. 2007;128(1):129–139. doi:10.1016/j.cell.2006.11.039
   PubMed Web of Science ®Google Scholar
• Seimiya M, O-Wang J, Bahar R, et al. Stage-specific expression of Clast6/E3/LAPTM5 during B cell differentiation: elevated expression in human B lymphomas. INT J ONCOL. 2003;22(2):301–304.
   PubMed Web of Science ®Google Scholar
• Kawano Y, Ouchida R, Wang J-Y, et al. A novel mechanism for the autonomous termination of pre-B cell receptor expression via induction of lysosome-associated protein transmembrane 5. Mol Cell Biol. 2012;32(21):4462–4471. doi:10.1128/MCB.00531-12
   PubMed Web of Science ®Google Scholar
• Zhang H, Wei Q, Liu R, et al. Overexpression of LAPTM4B-35: a novel marker of poor prognosis of prostate cancer. PLoS One. 2014;9(3):e91069. doi:10.1371/journal.pone.0091069
   PubMed Web of Science ®Google Scholar
• Xiao M, Jia S, Wang H, et al. Overexpression of LAPTM4B: an independent prognostic marker in breast cancer. J Cancer Res Clin Oncol. 2013;139(4):661–667. doi:10.1007/s00432-012-1368-y
   PubMed Web of Science ®Google Scholar
• Shao GZ, Zhou R-L, Zhang Q-Y, et al. Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma. Oncogene. 2003;22(32):5060–5069. doi:10.1038/sj.onc.1206832
   PubMed Web of Science ®Google Scholar
• Sui Y, Lu K, Fu L. Prediction and analysis of novel key genes ITGAX, LAPTM5, SERPINE1 in clear cell renal cell carcinoma through bioinformatics analysis. PeerJ. 2021;9:e11272. doi:10.7717/peerj.11272
   PubMed Web of Science ®Google Scholar
• Xiong Y, Wei Y, Gu Y, et al. DiseaseMeth version 2.0: a major expansion and update of the human disease methylation database. Nucleic Acids Res. 2017;45(D1):D888–D895. doi:10.1093/nar/gkw1123
   PubMed Web of Science ®Google Scholar
• Xu Y, Wu G, Li J, et al. Screening and identification of key biomarkers for bladder cancer: a study based on TCGA and GEO data. Biomed Res Int. 2020;2020:8283401. doi:10.1155/2020/8283401
   PubMed Web of Science ®Google Scholar
• Xu Y, Li X, Han Y, et al. A new prognostic risk model based on PPAR pathway-related genes in kidney renal clear cell carcinoma. PPAR Res. 2020;2020:6937475. doi:10.1155/2020/6937475
   PubMed Web of Science ®Google Scholar
• Nuylan M, Kawano T, Inazawa J, et al. Down-regulation of LAPTM5 in human cancer cells. Oncotarget. 2016;7(19):28320–28328. doi:10.18632/oncotarget.8614
   PubMedGoogle Scholar
• Chen L, Wang G, Luo Y, et al. Downregulation of LAPTM5 suppresses cell proliferation and viability inducing cell cycle arrest at G0/G1 phase of bladder cancer cells. Int J Oncol. 2017;50(1):263–271. doi:10.3892/ijo.2016.3788
   PubMed Web of Science ®Google Scholar
• Cortese R, Hartmann O, Berlin K, et al. Correlative gene expression and DNA methylation profiling in lung development nominate new biomarkers in lung cancer. Int J Biochem Cell Biol. 2008;40(8):1494–1508. doi:10.1016/j.biocel.2007.11.018
   PubMed Web of Science ®Google Scholar
• Inoue J, Misawa A, Tanaka Y, et al. Lysosomal-associated protein multispanning transmembrane 5 gene (LAPTM5) is associated with spontaneous regression of neuroblastomas. PLoS One. 2009;4(9):e7099. doi:10.1371/journal.pone.0007099
   PubMed Web of Science ®Google Scholar
• Hayami Y, Iida S, Nakazawa N, et al. Inactivation of the E3/LAPTm5 gene by chromosomal rearrangement and DNA methylation in human multiple myeloma. Leukemia. 2003;17(8):1650–1657. doi:10.1038/sj.leu.2403026
   PubMed Web of Science ®Google Scholar
• Bagratuni T, Mavrianou N, Gavalas NG, et al. JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer. Eur J Cancer. 2020;126:125–135. doi:10.1016/j.ejca.2019.11.017
   PubMed Web of Science ®Google Scholar